Effect of magnesium on poly cystic ovary syndrome

effect of magnesium supplementation on menstrual disorders, androgenic alopecia, quality of life and acne in women with poly cystic ovary syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130903014551N9

Enrollment

Registered

2020-10-18

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

poly cystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Patients in this group will receive 250 mg magnesium supplement made by Donya Daru Sepehr Company once a day for 10 weeks. Intervention 2: Control group: Patients i

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Women 18 to 45 years old with PCOS BMI between 5/18 to 30 Do not change the dose of the drug or start taking a new drug in the last two weeks Absence of menopause Absence of hypothyroidism Do not take vitamin and mineral supplements

Exclusion criteria

Exclusion criteria: Failure to follow nutritional recommendations and interventions Failure to refer the person in the next steps Change the dose of the drug or start taking a new drug that affects the indicators of the study Having a specific disease that disrupts the study process Occurrence of menopause

Design outcomes

Primary

Measure	Time frame
Menstrual disorder. Timepoint: Before and after intervention. Method of measurement: Based on standard definitions provided by the International Federation of Gynecology and Obstetrics.;Androgenic alopecia. Timepoint: Before and after intervention. Method of measurement: Sinclair Scale.;Quality of life. Timepoint: Before and after intervention. Method of measurement: Health Survey Questionnaire (SF-36.;Acne. Timepoint: Before and after intervention. Method of measurement: GAGS (global acne grading system) method.;Number of ovarian cysts. Timepoint: At the beginning and end of the intervention. Method of measurement: sonography.	—

Measure

Time frame

Menstrual disorder. Timepoint: Before and after intervention. Method of measurement: Based on standard definitions provided by the International Federation of Gynecology and Obstetrics.;Androgenic alopecia. Timepoint: Before and after intervention. Method of measurement: Sinclair Scale.;Quality of life. Timepoint: Before and after intervention. Method of measurement: Health Survey Questionnaire (SF-36.;Acne. Timepoint: Before and after intervention. Method of measurement: GAGS (global acne grading system) method.;Number of ovarian cysts. Timepoint: At the beginning and end of the intervention. Method of measurement: sonography.

—

Secondary

Measure	Time frame
Physical activity. Timepoint: In the second,forth,sixth,eighth and tenth weeks. Method of measurement: Physical activity record questionnaire.;Dietary intake. Timepoint: In the second,forth,sixth,eighth and tenth weeks. Method of measurement: food record.;Serum magnesium concentration. Timepoint: At the beginning the intervention, In the fifth week of the intervention. Method of measurement: AAS method.	—

Measure

Time frame

Physical activity. Timepoint: In the second,forth,sixth,eighth and tenth weeks. Method of measurement: Physical activity record questionnaire.;Dietary intake. Timepoint: In the second,forth,sixth,eighth and tenth weeks. Method of measurement: food record.;Serum magnesium concentration. Timepoint: At the beginning the intervention, In the fifth week of the intervention. Method of measurement: AAS method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsima Jaripur

Esfahan University of Medical Sciences

mahsimajaripur@ut.ac.ir+98 31 5546 1381

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026